Marshall Wace, LLP Amylyx Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.07 - $18.46 $2.57 Million - $3.93 Million	-212,646 Reduced 17.75%	985,114 $14.5 Million
Q3 2023 Nov 14, 2023	SELL	$18.08 - $23.45 $14.1 Million - $18.3 Million	-782,420 Reduced 39.51%	1,197,760 $21.9 Million
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $17.6 Million - $26.4 Million	840,940 Added 73.82%	1,980,180 $42.7 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $31.6 Million - $46.6 Million	1,139,240 New	1,139,240 $33.4 Million
Q3 2022 Nov 14, 2022	SELL	$17.15 - $30.92 $5.44 Million - $9.81 Million	-317,309 Reduced 48.2%	341,064 $9.6 Million
Q2 2022 Aug 15, 2022	BUY	$6.85 - $19.93 $506,276 - $1.47 Million	73,909 Added 12.65%	658,373 $12.7 Million
Q1 2022 May 16, 2022	BUY	$12.85 - $32.9 $7.51 Million - $19.2 Million	584,464 New	584,464 $7.51 Million

139

46.5M

226K

909K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $290M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.